Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Lori Eaton

Nurse Practitioner, Psychiatric/Mental Health Manchester, NH Nurse Practitioner

NPI 1720331846 CMS profile 11158551

1555 Elm St, Manchester, NH 03101

Open in the dashboard

General payments

$4,116

172 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Lori Eaton of Manchester, NH is reported in the CMS Open Payments database as having received $4,116 across 172 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $430 9
2023 General $831 25
2022 General $1,452 71
2021 General $1,404 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lori Eaton
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Lori Eaton were reported at $0. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Lori Eaton Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,404 $166 $54–$482 $132
2022 $1,452 $195 $66–$559 $149
2023 $831 $233 $82–$673 $160
2024 $430 $236 $84–$688 $164
2025 $0 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. AbbVie, Inc. $1,147 47 payments
  2. Vanda Pharmaceuticals Inc. $1,070 37 payments
  3. Teva Pharmaceuticals USA, Inc. $385 24 payments
  4. Neurocrine Biosciences, Inc. $252 6 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $209 10 payments
  6. Supernus Pharmaceuticals, Inc. $197 11 payments
  7. Alkermes, Inc. $188 6 payments
  8. Axsome Therapeutics, Inc. $179 3 payments
  9. Lundbeck LLC $163 9 payments
  10. Bausch Health US, LLC $102 6 payments
  11. Other $224 13 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $4,116 172 payments
Products named General payments · program years 2021–2024
  1. VRAYLAR $1,147 47 payments
  2. HETLIOZ $1,070 37 payments
  3. FANAPT $1,070 37 payments
  4. AUSTEDO $289 23 payments
  5. INGREZZA $252 6 payments
  6. QELBREE $197 11 payments
  7. TRINTELLIX $185 9 payments
  8. Auvelity $179 3 payments
  9. REXULTI $163 9 payments
  10. LYBALVI $162 4 payments
  11. Other $1,004 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

45

Median for Nurse Practitioner: 389

Drug cost

$1,278

Median for Nurse Practitioner: $21,885

Branded share of claims

0%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydroxyzine Hcl Generic 19 $1,130
Clonazepam Generic 14 $131
Diazepam Generic 12 $17

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $150
$150 — —
Auvelity
  • Axsome Therapeutics, Inc. $125
$125 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $111
$111 — —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $45
$45 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

172 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in New Hampshire

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record